stoxline Quote Chart Rank Option Currency Glossary
Achilles Therapeutics plc (ACHL)
0.82  0.021 (2.63%)    04-23 10:59
Open: 0.7901
High: 0.83
Volume: 29,231
Pre. Close: 0.799
Low: 0.7901
Market Cap: 34(M)
Technical analysis
2024-04-23 10:46:17 AM
Short term     
Mid term     
Targets 6-month :  1.29 1-year :  1.54
Resists First :  1.1 Second :  1.32
Pivot price 0.85
Supports First :  0.75 Second :  0.63
MAs MA(5) :  0.8 MA(20) :  0.94
MA(100) :  0.99 MA(250) :  0.95
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  6.8 D(3) :  4
RSI RSI(14): 34.8
52-week High :  1.75 Low :  0.74
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ ACHL ] has closed above bottom band by 42.1%. Bollinger Bands are 19.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.82 - 0.83 0.83 - 0.83
Low: 0.75 - 0.75 0.75 - 0.76
Close: 0.78 - 0.79 0.79 - 0.8
Company Description

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. The company was founded in 2016 and is headquartered in London, the United Kingdom.

Headline News

Fri, 05 Apr 2024
Achilles Therapeutics reports Q4 EPS (46c) vs. (61c) last year - - TipRanks

Thu, 04 Apr 2024
Nasdaq Surges 1%; ConAgra Brands Posts Upbeat Earnings - Achilles Therapeutics (NASDAQ:ACHL), Allurion Te - Benzinga

Thu, 04 Apr 2024
Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights - GlobeNewswire

Thu, 04 Apr 2024
Achilles Therapeutics GAAP EPS of -$0.46 misses by $0.32 (NASDAQ:ACHL) - Seeking Alpha

Mon, 01 Apr 2024
Achilles Therapeutics (ACHL) Scheduled to Post Quarterly Earnings on Tuesday - MarketBeat

Wed, 06 Mar 2024
Where Does Achilles Therapeutics PLC (ACHL) Stock Fall in the Biotechnology Field After It Has Fallen -22.29% This Week? - InvestorsObserver

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 42 (M)
Shares Float 22 (M)
Held by Insiders 5.8 (%)
Held by Institutions 50.8 (%)
Shares Short 75 (K)
Shares Short P.Month 154 (K)
Stock Financials
EPS -1.75
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 3.46
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -24.7 %
Return on Equity (ttm) -41.1 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.7
Qtrly Earnings Growth 0 %
Operating Cash Flow -48 (M)
Levered Free Cash Flow -28 (M)
Stock Valuations
PE Ratio -0.48
PEG Ratio -0.2
Price to Book value 0.23
Price to Sales 0
Price to Cash Flow -0.71
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android